New therapeutic solutions for Behçet’s syndrome

References

• Gül A. Behçet’s disease: an update on the pathogenesis. Clin Exp Rheumatol. 2001;19:S6–S12.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Yazici Y, Yazici H. Behçet’s syndrome. Rheum Dis Clin North Am. 2013;39:245–261.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Cantarini L, Vitale A, et al. Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediators Inflamm. 2015;2015:194864.
   PubMed Web of Science ®Google Scholar
• Rigante D, Vitale A, Lucherini OM, et al. The hereditary autoinflammatory disorders uncovered. Autoimmun Rev. 2014;13:892–900.
   PubMed Web of Science ®Google Scholar
• Caso F, Rigante D, Vitale A, et al. Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol. 2013;2013:513782.
   PubMedGoogle Scholar
• Gül A. Pathogenesis of Behçet’s disease: autoinflammatory features and beyond. Semin Immunopathol. 2015;37:413–418.
   PubMed Web of Science ®Google Scholar
• Pineton De Chambrun M, Wechsler B, Geri G, et al. New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev. 2012;11:687–698.
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1–11.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Ito M, Nakagawa A, et al. Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behçet disease. Histopathology. 2000;36:362–371.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656–1662.
   PubMed Web of Science ®Google Scholar
• Kotter I, Gunaydin I, Batra M, et al. CNS involvement occurs more frequently in patients with Behçet’s disease under cyclosporin A (CSA) than under other medications – results of a retrospective analysis of 117 cases. Clin Rheumatol. 2006;25:482–486.
   PubMed Web of Science ®Google Scholar
• Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67–74.
   PubMed Web of Science ®Google Scholar
• Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behçet’s disease: experience in 19 patients. Rheumatology (Oxford). 2012;51:1825–1831.
   PubMed Web of Science ®Google Scholar
• Pipitone N, Olivieri I, Padula A, et al. Infliximab for the treatment of Neuro-Behçet’s disease: a case series and review of the literature. Arthritis Rheum. 2008;59:285–290.
   PubMed Web of Science ®Google Scholar
• Arida A, Fragiadaki K, Giavri E, et al., Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41:61–70.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Victoria Hernández M, Llorenç V, et al. Behçet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm. 2013;21:160–162.
   PubMed Web of Science ®Google Scholar
• Botsios C, Sfriso P, Furlan A, et al. Resistant Behçet disease responsive to anakinra. Ann Intern Med. 2008;149:284–286.
   PubMed Web of Science ®Google Scholar
• Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease. Clin Rheumatol. 2010;29:209–210.
   PubMed Web of Science ®Google Scholar
• Emmi G, Silvestri E, Cameli AM, et al. Anakinra for resistant Behçet uveitis: why not? Clin Exp Rheumatol. 2013;31:152–153.
   PubMed Web of Science ®Google Scholar
• Caso F, Rigante D, Vitale A, et al. Efficacy of anakinra in refractory Behçet’s disease sacroiliitis. Clin Exp Rheumatol. 2014;32:S171.
   PubMed Web of Science ®Google Scholar
• Rotondo C, Lopalco G, Iannone F, et al. Mucocutaneous involvement in Behçet’s disease: how systemic treatment has changed in the last decades and future perspectives. Mediators Inflamm. 2015;2015:451675.
   PubMed Web of Science ®Google Scholar
• Emmi G, Silvestri E, Ciucciarelli L, et al. Reply: anti-IL1 blocking agents in drug-resistant Behçet’s syndrome: our little case series. Clin Exp Rheumatol. 2014;32:S172.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Pucino V, Vitale A, et al. Immunometabolic biomarkers of inflammation in Behçet’s disease: relationship with epidemiological profile, disease activity and therapeutic regimes. Clin Exp Immunol. 2016.Epub 2016 Jan 12. doi:10.1111/cei.12768.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Lucherini OM, Vitale A, et al. Putative role of serum amyloid-A and proinflammatory cytokines as biomarkers for Behçet’s disease. Medicine (Baltimore). 2015;94:e1858.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behçet’s disease: a case series. Clin Rheumatol. 2015;34:1293–1301.
   PubMed Web of Science ®Google Scholar
• Vitale A, Rigante D, Caso F, et al. Interleukin-1 blockade in neuro-Behçet’s disease: a case-based reflection. Int J Rheum Dis. 2015. Epub 2015 May27. doi:10.1111/1756-185X.12680.
   Web of Science ®Google Scholar
• Ugurlu S, Ucar D, Seyahi E, et al. Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis. 2012;71:1589–1591.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Borri M, et al. Successful use of canakinumab in a patient with resistant Behçet’s disease. Clin Exp Rheumatol. 2012;30:S115.
   PubMed Web of Science ®Google Scholar
• Vitale A, Rigante D, Caso F, et al. Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet’s disease: a case series. Dermatology. 2014;228:211–214.
   PubMed Web of Science ®Google Scholar
• Pagnini I, Bondi T, Simonini G, et al. Successful treatment with canakinumab of a paediatric patient with resistant Behçet’s disease. Rheumatology (Oxford). 2015;54:1327–1328.
   PubMed Web of Science ®Google Scholar
• Emmi G, Talarico R, Lopalco G, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study. Clin Rheumatol. 2015.Epub 2015 Jul 10. doi:10.1007/s10067-015-3004-0.
   Web of Science ®Google Scholar
• Cantarini L, Talarico R, Generali E, et al. Safety profile of biologic agents for Behçet’s disease in a multicenter observational color study. Int J Rheum Dis. 2015.Epub 2015 Aug 18. doi:10.1111/1756-185X.12732.
   Google Scholar
• Grayson PC, Yazici Y, Novakovich E, et al. Treatment of mucocutaneous manifestations in Behçet’s disease with Anakinra: a pilot open-label study. [ cited 2016 Jan 31]. Available from: http://acrabstracts.org/abstract/treatment-of-mucocutaneous-manifestations-in-behcets-disease-with-anakinra-a-pilot-open-label-study/.
   Google Scholar
• Gül A, Tugal-Tutkun I, Dinarello CA, et al. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet’s disease: an open-label pilot study. Ann Rheum Dis. 2012;71:563–566.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Kadayifcilar S, Khairallah M, et al. Safety and efficacy of gevokizumab in patients with Behçet’s disease uveitis: results of an exploratory phase 2 study. Ocul Immunol Inflamm. 2016.Epub2016 Jan 30. doi:10.3109/09273948.2015.1092558.
   Google Scholar
• Cantarini L, Lopalco G, Caso F, et al. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet’s disease. Autoimmun Rev. 2015;14:1–9.
   PubMed Web of Science ®Google Scholar
• Caso F, Iaccarino L, Bettio S, et al. Refractory pemphigus foliaceus and Behçet’s disease successfully treated with tocilizumab. Immunol Res. 2013;56:390–397.
   PubMed Web of Science ®Google Scholar
• Hirano T, Ohguro N, Hohki S, et al. A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol. 2012;22:298–302.
   PubMed Web of Science ®Google Scholar
• Redondo-Pachón MD, Enríquez R, Sirvent AE, et al. Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behçet’s disease. Ren Fail. 2013;35:547–550.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Lopalco G, Vitale A, et al. Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab. Clin Rheumatol. 2015;34:1141–1143.
   PubMed Web of Science ®Google Scholar
• Diamantopoulos AP, Hatemi G. Lack of efficacy of tocilizumab in mucocutaneous Behçet’s syndrome: report of two cases. Rheumatology (Oxford). 2013;52:1923–1924.
   PubMed Web of Science ®Google Scholar
• Papo M, Bielefeld P, Vallet H, et al. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol. 2014;32:S75–S79.
   PubMed Web of Science ®Google Scholar
• Addimanda O, Pipitone N, Pazzola G, et al. Tocilizumab for severe refractory neuro-Behçet: three cases IL-6 blockade in neuro-Behçet. Semin Arthritis Rheum. 2015;44:472–475.
   PubMed Web of Science ®Google Scholar
• Urbaniak P, Hasler P, Kretzschmar S. Refractory neuro-Behçet treated by tocilizumab: a case report. Clin Exp Rheumatol. 2012;30:S73–S75.
   Google Scholar
• Shapiro LS, Farrell J, Borhani Haghighi A. Tocilizumab treatment for neuro-Behçet’s disease, the first report. Clin Neurol Neurosurg. 2012;114:297–298.
   PubMed Web of Science ®Google Scholar
• Hamzaoui K, Hamzaoui A, Guemira F, et al. Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scand J Rheumatol. 2002;31:205–210.
   PubMed Web of Science ®Google Scholar
• Borhani HA, Ittehadi H, Nikseresht AR, et al. CSF levels of cytokines in neuro-Behçet’s disease. Clin Neurol Neurosurg. 2009;111:507–510.
   PubMed Web of Science ®Google Scholar
• Akman-Demir G, Tüzün E, Içöz S, et al. Interleukin-6 in neuro-Behçet’s disease: association with disease subsets and long-term outcome. Cytokine. 2008;44:373–376.
   PubMed Web of Science ®Google Scholar
• Hirohata S, Isshi K, Oguchi H, et al. Cerebrospinal fluid interleukin-6 in progressive Neuro-Behçet’s syndrome. Clin Immunol Immunopathol. 1997;82:12–17.
   PubMedGoogle Scholar
• Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behçet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13:246–252.
   PubMed Web of Science ®Google Scholar
• Sadreddini S, Noshad H, Molaeefard M, et al. Treatment of retinal vasculitis in Behçet’s disease with rituximab. Mod Rheumatol. 2008;18:306–308.
   PubMed Web of Science ®Google Scholar
• Zhao BH, Oswald AE. Improved clinical control of a challenging case of Behçet’s disease with rituximab therapy. Clin Rheumatol. 2014;33:149–150.
   PubMed Web of Science ®Google Scholar
• Messina MJ, Rodegher M, Scotti R, et al. Treatment of myelitis in Behçet’s disease with rituximab. BMJ Case Rep. 2014;2014.
   PubMedGoogle Scholar
• Pelegrin L, Jakob E, Schmidt-Bacher A, et al. Experiences with rituximab for the treatment of autoimmune diseases with ocular involvement. J Rheumatol. 2014;41:84–90.
   PubMed Web of Science ®Google Scholar
• Havari E, Turner MJ, Campos-Rivera J, et al. Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. Immunology. 2014;141:123–131.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Hoshi K, Matsuda T, et al. Increased peripheral blood gamma delta+ T cells and natural killer cells in Behçet’s disease. J Rheumatol. 1992;19:588–592.
   PubMed Web of Science ®Google Scholar
• Esin S, Gül A, Hodara V, et al. Peripheral blood T cell expansions in patients with Behçet’s disease. Clin Exp Immunol. 1997;107:520–527.
   PubMed Web of Science ®Google Scholar
• Dalghous AM, Freysdottir J, Fortune F. Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behçet’s disease (BS) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BS. Scand J Rheumatol. 2006;35:472–475.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Smith RM, Chow YW, et al. Alemtuzumab as remission induction therapy in Behçet disease: A 20-year experience. J Rheumatol. 2015;42:1906–1913.
   PubMed Web of Science ®Google Scholar
• Perez-Pampin E, Campos-Franco J, Blanco J, et al. Remission induction in a case of refractory Behçet disease with alemtuzumab. J Clin Rheumatol. 2013;19:101–103.
   PubMed Web of Science ®Google Scholar
• Baerveldt EM, Kappen JH, Thio HB, et al. Successful long-term triple disease control by ustekinumab in a patient with Behçet’s disease, psoriasis and hidradenitis suppurativa. Ann Rheum Dis. 2013;72:626–627.
   PubMed Web of Science ®Google Scholar
• Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A. 1994;91:1198–1205.
   PubMed Web of Science ®Google Scholar
• Tsambaos D, Eichelberg D, Goos M. Behçet’s syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermato Res. 1986;278:335–336.
   PubMed Web of Science ®Google Scholar
• Aydinoglu-Candan Ö, Araz-Erşan B, Gul A, et al., Anti-interferon alpha antibodies and autoantibodies in patients with Behçet’s disease uveitis treated with recombinant human interferon alpha-2a. Graefes Arch Clin Exp Ophthalmol. 2015;253:457–465.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Xenitidis T, Schoenfisch B, et al. Interim analysis of the clinical trial INCYTOB (interferon alpha-2a versus cyclosporin A for the treatment of severe ocular Behçet’s disease). Iovs. 2011 [cited 2016 Jan 31];52:4254. Available from: http://iovs.arvojournals.org/article.aspx?articleid=2356389.
   Google Scholar
• Deuter CM, Zierhut M, Möhle A, et al. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet’s disease. Arthritis Rheum. 2010;62:2796–2805.
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138:467–471.
   PubMed Web of Science ®Google Scholar
• Kötter I, Vonthein R, Zierhut M, et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial. Semin Arthritis Rheum. 2004;33:311–319.
   PubMed Web of Science ®Google Scholar
• Yalçindağ FN, Uzun A. Results of interferon alpha-2a therapy in patients with Behçet’s disease. J Ocul Pharmacol Ther. 2012;28:439–443.
   PubMed Web of Science ®Google Scholar
• Kiliç H, Zeytin HE, Korkmaz C, et al. Low-dose natural human interferon-alpha lozenges in the treatment of Behçet’s syndrome. Rheumatology (Oxford). 2009;48:1388–1391.
   PubMed Web of Science ®Google Scholar
• Plskova J, Greiner K, Muckersie E, et al. Interferon-alpha: a key factor in autoimmune disease? Invest Ophthalmol Vis Sci. 2006;47:3946–3950.
   PubMed Web of Science ®Google Scholar
• Kötter I, Hamuryudan V, Oztürk ZE, et al. Interferon therapy in rheumatic diseases: state-of-the-art 2010. Curr Opin Rheumatol. 2010;22:278–283.
   PubMed Web of Science ®Google Scholar
• Kumar N, Goldminz AM, Kim N, et al. Phosphodiesterase 4-targeted treatments for autoimmune diseases. BMC Med. 2013;11:96.
   PubMed Web of Science ®Google Scholar
• Wittmann M, Helliwell PS. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. Dermatol Ther (Heidelb). 2013;3:1–15.
   PubMedGoogle Scholar
• Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387–1399.
   PubMed Web of Science ®Google Scholar
• Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64:3156–3167.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behçet’s syndrome–a phase 2, placebo-controlled study. N Engl J Med. 2015;372:1510–1518.
   PubMed Web of Science ®Google Scholar
• Soysal T, Salihoğlu A, Esatoğlu SN, et al. Bone marrow transplantation for Behçet’s disease: a case report and systematic review of the literature. Rheumatology (Oxford). 2014;53:1136–1141.
   PubMed Web of Science ®Google Scholar
• Kook MH, Yhim HY, Lee NR, et al. Successful treatment of myelodysplastic syndrome and Behcet colitis after allogeneic hematopoietic stem cell transplantation. Korean J Intern Med. 2014;29:123–125.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Nikbin B, Shams H, et al. Mesenchymal stem cell therapy unable to rescue the vision from advanced Behcet’s disease retinal vasculitis: report of three patients. Int J Rheum Dis. 2013;16:139–147.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Shimizu N, Tougasaki E, et al. Successful treatment by azacitidine therapy of intestinal Behçet’s disease associated with myelodysplastic syndrome. Int J Hematol. 2013;97:520–524.
   PubMed Web of Science ®Google Scholar
• Shugaiv E, Tüzün E, Mutlu M, et al. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behçet’s disease with parenchymal involvement: presentation of four cases. Clin Exp Rheumatol. 2011;29:S64–67.
   PubMed Web of Science ®Google Scholar
• Neri P, Mariotti C, Cimino L, et al. Long-term control of cystoid macular oedema in noninfectious uveitis with mycophenolate mofetil. Int Ophthalmol. 2009;29:127–133.
   PubMedGoogle Scholar
• Adler YD, Mansmann U, Zouboulis CC. Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet’s disease. Dermatology. 2001;203:322–324.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Rigante D, Vitale A, et al. Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future. Immunol Res. 2015;61:326–337.
   PubMed Web of Science ®Google Scholar
• Seider N, Beiran I, Scharf J, et al. Intravenous immunoglobulin therapy for resistant ocular Behçet’s disease. Br J Ophthalmol. 2001;85:1287–1288.
   PubMed Web of Science ®Google Scholar
• Rewald E, Jaksic JC. Behçet’s syndrome treated with high-dose intravenous IgG and low-dose aspirin. J R Soc Med. 1990;83:652–653.
   PubMed Web of Science ®Google Scholar
• Beales IL. Gastrointestinal involvement in Behçet’s syndrome. Am J Gastroenterol. 1998;93:2633.
   PubMed Web of Science ®Google Scholar
• Shutty B, Garg KJ, Swender D, et al. Optimal use of IVIG in a patient with Behçet syndrome and common variable immunodeficiency. Ann Allergy Asthma Immunol. 2012;109:84.
   PubMed Web of Science ®Google Scholar
• Wechsler B, Sablé-Fourtassou R, Bodaghi B, et al. Infliximab in refractory uveitis due to Behçet’s disease. Clin Exp Rheumatol. 2004;22:S14–S16.
   PubMed Web of Science ®Google Scholar
• Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120:777–787.
   PubMed Web of Science ®Google Scholar
• Buggage RR, Levy-Clarke G, Sen HN, et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet’s disease. Ocul Immunol Inflamm. 2007;15:63–70.
   PubMed Web of Science ®Google Scholar